About the Leukemia Program
As one of the largest and most comprehensive pediatric leukemia treatment programs in the country, we provide diagnosis, evaluation and ongoing management to over 500 pediatric patients with suspected or diagnosed acute lymphoblastic leukemia, acute myeloid leukemia and chronic leukemias each year. The Leukemia Program offers individualized therapies for every type and phase of leukemia seen in infants, children, adolescents and young adults. Leukemia treatment is delivered by a highly competent, experienced and diverse staff of doctors and cancer researchers.
Our multidisciplinary team of physicians and staff sees patients for initial treatment and ongoing care. Experts in pediatric oncology, pediatric surgery, cell and gene therapy including stem cell transplant, radiation oncology, pediatric anesthesia, pharmacology, social work, child life and the full complement of pediatric subspecialty services put a strong focus on family-centered care and emotional support for both the child and the family.
Treatment options include chemotherapy, Phase 1 investigational therapies, radiation therapy (both conventional and proton), bone marrow transplantation and immunotherapy. Each patient receives individualized treatment according to his or her diagnosis.
In addition, we have dedicated and state-of-the-art hematology, cytogenetics, flow cytometry and molecular pathology laboratories which conduct comprehensive testing and provide timely and accurate patient results.
The Leukemia Program conducts numerous clinical trials for children with newly diagnosed leukemias, and for children with recurrent and resistant disease. All patients are considered for eligibility to participate in clinical trials, which are the standard of care for our patients. The program is unique in its concentration of nationally and internationally recognized leaders in the areas of new drug development, cell and gene therapy and design and conduct of both local and national clinical trials through the Children’s Oncology Group (COG).
Texas Children’s Cancer Center is a member of the COG Phase I Consortium, a small and select group of institutions that administer Phase I clinical trials of drugs in early development.
Research in the Leukemia Program spans from direction of clinical trials to basic molecular studies of leukemia biology, immunotherapy and development of novel agents, and to mitigating the late effects of treatment in long-term survivors. The Leukemia Program is dedicated to integrating laboratory and clinical research to increase our understanding of leukemia and to develop new, more effective therapies for the disease.